Business
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio of products. For more detail
About this update from Mbx Biosciences, Inc.
[{"type":"image","alt":"MBX Biosciences, Inc.","displaySize":"","headline":null,"caption":"MBX Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8cd3831a50ba14ff9e3ffa7d6e7ec405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_C0n7VcB_HB0.oFrvSxAdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NQ--/https://media.zenfs.com/en/globenewswire.com/8cd3831a50ba14ff9e3ffa7d6e7ec405","width":300,"height":118}},"lazy":false},{"type":"text","content":"CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio of products. For more details and to register for the event, click here.","length":549,"tagName":"p"},{"type":"text","content":"The event will feature Richard DiMarchi, Ph.D. (Distinguished Professor of Chemistry, Indiana University; Scientific Co-Founder, MBX Biosciences, Inc.) and Katherine H. Saunders, M.D. (Co-Founder, FlyteHealth; Clinical Assistant Professor of Medicine, Weill Cornell Medicine), who will join company management to discuss the evolving treatment landscape and remaining treatment gaps in obesity.","length":409,"tagName":"p"},{"type":"text","content":"MBX management will provide an overview of MBX’s Precision Endocrine Peptide™ (PEP™) platform and its application to the development of long-acting peptide therapies for obesity, as well as an update on the Company’s obesity product candidates.","length":244,"tagName":"p"},{"type":"text","content":"A live Q&A session will follow the formal presentations.","length":60,"tagName":"p"},{"type":"text","content":"The live webcast can be accessed in the Events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. A replay of the webcast will be archived on the Company’s website for approximately 90 days.","length":235,"tagName":"p"},{"type":"text","content":"About Richard DiMarchi, Ph.D.","length":29,"tagName":"p"},{"type":"t...